Late-Onset Adrenal Insufficiency More Than 1 Year after Stopping Pembrolizumab
- 1 March 2018
- journal article
- letter
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 13 (3), e39-e40
- https://doi.org/10.1016/j.jtho.2017.10.023
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Two cases of late-onset secondary adrenal insufficiency after discontinuation of nivolumabAnnals of Oncology, 2017
- Adrenal Insufficiency Related to Anti-Programmed Death-1 TherapyAnticancer Research, 2017
- Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathiesNature Reviews Endocrinology, 2017
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine, 2016
- Immune-related adverse events with immune checkpoint blockade: a comprehensive reviewEuropean Journal Of Cancer, 2016
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 2015